AU2018347331A1 - Combination of a PARP inhibitor and a PD-1 axis binding antagonist - Google Patents

Combination of a PARP inhibitor and a PD-1 axis binding antagonist Download PDF

Info

Publication number
AU2018347331A1
AU2018347331A1 AU2018347331A AU2018347331A AU2018347331A1 AU 2018347331 A1 AU2018347331 A1 AU 2018347331A1 AU 2018347331 A AU2018347331 A AU 2018347331A AU 2018347331 A AU2018347331 A AU 2018347331A AU 2018347331 A1 AU2018347331 A1 AU 2018347331A1
Authority
AU
Australia
Prior art keywords
cancer
patient
ddr
treatment
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018347331A
Other languages
English (en)
Inventor
John Andrew BLAKE-HASKINS
Christoffel Hendrik BOSHOFF
Rossano CESARI
Dimitry Serge Antoine Nuyten
Ross Anthony Stewart
Fabian ZOHREN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Pfizer Inc
Original Assignee
Merck Patent GmbH
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Pfizer Inc filed Critical Merck Patent GmbH
Publication of AU2018347331A1 publication Critical patent/AU2018347331A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018347331A 2017-10-13 2018-10-10 Combination of a PARP inhibitor and a PD-1 axis binding antagonist Abandoned AU2018347331A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762572024P 2017-10-13 2017-10-13
US62/572,024 2017-10-13
US201862697587P 2018-07-13 2018-07-13
US62/697,587 2018-07-13
PCT/US2018/055174 WO2019075032A1 (en) 2017-10-13 2018-10-10 COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST

Publications (1)

Publication Number Publication Date
AU2018347331A1 true AU2018347331A1 (en) 2020-04-09

Family

ID=64049735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018347331A Abandoned AU2018347331A1 (en) 2017-10-13 2018-10-10 Combination of a PARP inhibitor and a PD-1 axis binding antagonist

Country Status (13)

Country Link
US (1) US20200254091A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694551A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020536887A (cg-RX-API-DMAC7.html)
KR (1) KR20200071097A (cg-RX-API-DMAC7.html)
CN (1) CN111225685A (cg-RX-API-DMAC7.html)
AU (1) AU2018347331A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020006371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078806A1 (cg-RX-API-DMAC7.html)
IL (1) IL273994A (cg-RX-API-DMAC7.html)
MX (1) MX2020003361A (cg-RX-API-DMAC7.html)
RU (1) RU2020113246A (cg-RX-API-DMAC7.html)
TW (1) TW201922288A (cg-RX-API-DMAC7.html)
WO (1) WO2019075032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019006504A2 (pt) * 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20230338521A1 (en) * 2020-05-04 2023-10-26 Merck Sharp & Dohme Llc Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor
EP4313034A1 (en) * 2021-03-24 2024-02-07 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
US10570202B2 (en) * 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
BR112017000672A2 (pt) * 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
EP3227337A1 (en) * 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
KR20170132171A (ko) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 pd­1 / pd­l1 저해제
EP3303397A1 (en) * 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌

Also Published As

Publication number Publication date
MX2020003361A (es) 2020-07-29
CA3078806A1 (en) 2019-04-18
US20200254091A1 (en) 2020-08-13
BR112020006371A2 (pt) 2020-09-29
CN111225685A (zh) 2020-06-02
TW201922288A (zh) 2019-06-16
IL273994A (en) 2020-05-31
RU2020113246A (ru) 2021-11-15
EP3694551A1 (en) 2020-08-19
RU2020113246A3 (cg-RX-API-DMAC7.html) 2021-11-15
WO2019075032A1 (en) 2019-04-18
JP2020536887A (ja) 2020-12-17
KR20200071097A (ko) 2020-06-18

Similar Documents

Publication Publication Date Title
TWI823859B (zh) 癌症之治療及診斷方法
US20200254091A1 (en) Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
TWI748942B (zh) 用於治療癌症之pd-1 / pd-l1抑制劑
AU2015214390B2 (en) Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
CA3165187A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
EP3355902B1 (en) Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
TW201819640A (zh) 癌症之治療性及診斷性方法
AU2018389196A1 (en) Methods and combination therapy to treat cancer
CN107532217A (zh) 用于癌症的治疗和诊断方法
CN107667119A (zh) 用于癌症的治疗和诊断方法
US20190216923A1 (en) Methods and combination therapy to treat cancer
US20200368205A1 (en) Methods and combination therapy to treat cancer
WO2019139583A1 (en) Methods and combination therapy to treat cancer
US20190211102A1 (en) Methods and combination therapy to treat cancer
HK40019847A (en) Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW202320848A (zh) 治療癌症之方法及組成物
HK40031470A (en) Methods and combination therapy to treat cancer
HK40010365B (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK40016679A (en) Therapeutic and diagnostic methods for cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period